Vienna - Delayed Quote • EUR Fresenius SE & Co. KGaA (FRE.VI) Follow 27.25 +0.01 (+0.04%) At close: April 26 at 5:32 PM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for FRE.VI 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: FRE.VI View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Is Now The Time To Look At Buying Fresenius SE & Co. KGaA (ETR:FRE)? Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue? Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last? Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital Fresenius Kabi receives FDA warning letter over issues at ex-Ivenix site Fresenius brings dialysis technology to US with FDA clearance Is Fresenius SE & Co. KGaA (ETR:FRE) Trading At A 45% Discount? The past five years for Fresenius SE KGaA (ETR:FRE) investors has not been profitable Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound? Individual investors account for 43% of Fresenius SE & Co. KGaA's (ETR:FRE) ownership, while institutions account for 30% Analysts Just Shaved Their Fresenius SE & Co. KGaA (ETR:FRE) Forecasts Dramatically Fresenius to develop AI models for dialysis care with new database of over 540,000 patients
